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Background: Despite signiﬁcant advances, the
treatment of diabetic foot ulcers (DFUs) remains a
major therapeutic challenge for clinicians, surgeons,
and other health care professionals. There is an urgent
need for new strategies with clinically effective inter-
ventions to treat DFUs to reduce the burden of care in
an efﬁcient and cost-effective way.
Objective: This randomized trial evaluated and
compared the clinical effectiveness, tolerability, and
costs of clostridial collagenase ointment (CCO) de-
bridement to that of debridement using saline mois-
tened gauze (SMG) and selective sharp debridement
for the treatment of DFUs.
Methods: Randomized, controlled, parallel group,
multicenter, open-label, 12-week study of 48 patients
with neuropathic DFUs randomized to 4 weeks of
treatment with either CCO or SMG after baseline
surgical debridement. The primary end point was the
condition of the ulcer bed at the end of treatment as
measured using a standardized wound assessment
tool. Secondary end points were the percentage
of reduction in wound area and therapeutic respo-
nse rates. Adverse events were monitored for the
tolerability analysis. In addition, a comparative cost-
effectiveness analysis was performed from the per-
spective of the Centers for Medicare and Medicaid
Services as a payer.*Members of the Collagenase Diabetic Foot Ulcer Study
Group are listed in the Acknowledgments.
November 2013Results: Both the CCO and SMG groups had
signiﬁcantly improved wound assessment scores
after 4 weeks of treatment (CCO, 2.5, P ¼
0.007; SMG, 3.4, P ¼ 0.006). Only CCO treat-
ment resulted in a statistically signiﬁcant decrease
from baseline in the mean wound area at the end of
treatment (P ¼ 0.0164) and at the end of follow-up
(P ¼ 0.012). In addition, the CCO group exhibited a
signiﬁcantly better response rate at the end of
follow-up compared with the SMG group (0.92
vs 0.75, P o 0.05). Reported adverse events were
similar between the 2 treatment groups. None of the
reported adverse events were considered to be
related to treatment. The economic analysis indi-
cated that the direct mean costs per responder in the
physician ofﬁce setting of care were $832 versus
$1042 for the CCO group versus the SMG group,
whereas the direct mean costs per responder in the
hospital outpatient department setting were $1607
versus $1980.2012, Phoenix, Arizona.
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Clinical TherapeuticsConclusions: CCO treatment provides equivalent
debridement of DFUs similar to SMG while fostering
better progress toward healing as measured by de-
creasing wound area over time and improved response
rates at the end of follow-up. In addition, CCO yields
a more favorable cost-effectiveness ratio in both the
physician ofﬁce and hospital outpatient department
settings of care. ClinicalTrials.gov identiﬁer:
NCT01056198. (Clin Ther. 2013;35:1805–1820)
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Kingdom).INTRODUCTION
Diabetic foot ulcers (DFUs) are a frequent and serious
complication of diabetes mellitus, with an annual
incidence rate of 1% to 4% and a lifetime risk of
15% to 25%.1–3 Typically, DFUs result from periph-
eral neuropathy and/or large vessel disease and are
complicated by deformity, callus, and trauma.1,2,4
Frequently, DFUs become infected and are a major
cause of hospital admissions and lower limb amputa-
tions.1–3 It has been reported that 40% to 70% of all
nontraumatic amputations of the lower limbs occur in
patients with diabetes and approximately 85% of
lower limb amputations in diabetic patients are
preceded by DFUs.4–6 Often, DFU-related amputa-
tions are associated with signiﬁcant morbidity and
mortality, along with immense social and psycholog-
ical consequences.7,8 In addition, DFUs and related
complications represent a signiﬁcant economic burden
that requires 20% to 40% of total health care
resources spent on diabetes management.9 The direct
treatment costs of DFU (adjusted to 2012 US dollars)
suggest that the mean annual costs per patient range
from $5643 to $25,590 and the mean cost per patient
per episode range from $9650 to $19,431.4,10–12 The
cost to treat a DFU during a 2-year period was
$27,987 in 1995 and increased to $46,841 in 2009
based on the medical component of the US Consumer
Price Index.4,13
The pathogenesis of DFU is complex and multifacto-
rial.14 Despite signiﬁcant progress and technological1806advances, the treatment of DFUs is a great challenge for
clinicians and other health care personnel. Debridement
of the nonviable material from the DFU bed has been
used for many years to enhance healing.15–17 Debride-
ment is thought to reduce the rate of infection and to
provide an ideal healing environment.18 There are several
procedures of debridement used in the management of
DFUs. These procedures include sharp surgical, enzymatic,
autolytic, mechanical, and hydrotherapy.15,16,18
Selective sharp debridement followed by saline moistened
cotton gauze has been used widely in managing these
wounds. This technique involves cutting away dead and
infected tissue followed by daily application of saline
moistened cotton gauze.19 Dead and infected tissue
adheres to the gauze as it dries. When the remoistened
gauze is removed to change the dressing each day, the
undesirable tissue comes with it. This action and subse-
quent sharp surgical debridements that are typically
performed as needed in weekly visits repeatedly remove
undesirable tissue.
Clostridial collagenase has been part of the arma-
mentarium for the debridement of wounds for nearly
50 years.20–26 During that time, numerous less speciﬁc
and potentially more destructive enzymatic debriders
(eg, papain/urea, ﬁbrinolysin, trypsin, and streptodor-
nase) have left or been removed from the market for
various reasons. Collagenase is an enzyme that effec-
tively removes detritus without harming healthy tis-
sue. It thereby contributes to the formation of
granulation tissue and subsequent epithelialization of
dermal ulcers. It is possible that collagenase may help
reset the conditions in the wound bed, stimulating
proliferation and migration of keratinocytes and
ﬁbroblasts by rendering the wound bed permissive
for migration or via the release of stimulatory peptide
fragments.27,28 Whether these effects are mediated
directly by collagenase contact with cells or through
byproducts of extracellular matrix digestion is not
clearly understood. However, evidence supports a role
for collagenase in aiding the extent and rate of wound
healing.27,29,30
A multicenter, 12-week randomized comparative
clinical trial was initiated to assess the relative effec-
tiveness of enzymatic debridement using clostridial
collagenase ointment *(CCO) with standard debri-
dement using saline moistened gauze (SMG) andVolume 35 Number 11
Table I. Key Eligibility Criteria.
Eligibility Criteria
Adults of any race and either sex
Full-thickness neuropathic foot ulcer, 0.5–10 cm2
(inclusive)
Ulcer duration of at least 1 month
Willing and able to perform dressing changes daily
at home
Willing and able to use appropriate off-loading
device
Adequate perfusion to target ulcer foot
(transcutaneous oxygen pressure 440 mm Hg
or toe pressure 440 mm Hg)
Adequate nutrition (albumin Z2.0 g/dL and
prealbumin Z15 mg/dL)
No active infection
No target wound tunneling
Target wound could not be on heel or over a
Charcot deformity
†Trademark: Steriluxs (Hartmann, Rock Hill, South Carolina).
‡Trademark: Allevyns (Smith & Nephew, Hull, United
Kingdom).
A. Tallis et al.selective sharp debridement in diabetic patients. The
SMG was selected as the comparator to CCO because
of its action as a mechanical debrider31 and, more
importantly, because it is not known to otherwise
promote wound healing, allowing its use as a negative
control in comparisons with CCO. Although gauze, in
particular wet-to-dry gauze, is not a generally recom-
mended dressing choice by wound care experts,32 it
remains a commonly used dressing in the United
States.32–34
In this randomized comparative clinical trial, we
sought to answer 3 important questions on the clinical
utility of CCO in the debridement of DFUs. First, how
effectively does the selective action of CCO clean the
DFU wound bed compared with SMG, which is
universally accepted as an effective, albeit nonselective,
technique to remove nonviable necrotic tissue? Second,
does wound reepithelialization proceed differently
between the 2 approaches (ie, does it progress appre-
ciably faster with CCO)? Third, how do the outcomes
achieved with the 2 methods compare economically
from the perspective of the US payer (ie, the Centers
for Medicare and Medicaid Services [CMS])?
PATIENTS AND METHODS
Study Participants
This study was registered at clinicaltrials.gov as
NCT01056198. Patients 18 years or older with a
diagnosis of type 1 or type 2 diabetes requiring medi-
cations to normalize blood glucose levels were included.
Eligible patients had neuropathic foot ulcers of at least 1
month’s duration between 0.5 and 10 cm2 in area. Key
eligibility criteria are presented in Table I. This study was
performed in compliance with the ethical principles of
the Declaration of Helsinki and Good Clinical Practice.
The study protocol, investigators, and consent
documents were reviewed and approved by accredited
institutional review boards, and all patients provided
written informed consent before taking part in the study.
Study Design
This was a randomized, parallel group, open-label,
multicenter, 12-week clinical study (Figure 1) performed
at 7 sites in Arizona, Nebraska, Pennsylvania, and
Texas. The study participants were recruited between
April 2010 and May 2011 when enrollment objectives
had been met. Randomization to treatment was
centralized. For each qualiﬁed patient, investigative
sites contacted the central call center for the nextNovember 2013sequential treatment assignment from a predetermined
computer-generated randomization sequence.
Patients with DFUs were evaluated for eligibility at
a Screening Visit that included a blood draw for
assessment of hematology and blood chemistry. Eligi-
ble patients reported for the baseline (randomization)
visit 1 to 5 days later. The baseline wound bed
assessment and measurement were performed fol-
lowed by sharp surgical debridement performed for
all patients. Patients were then randomly assigned to
treatment in an equal allocation ratio to either the
CCO group or SMG group. CCO was applied once
daily at the thickness of a nickel (2 mm) on the
DFUs of the patients in the CCO group and, saline
moistened cotton gauze† was applied and changed
daily for the patients in the SMG group. These
bandages were covered by an adhesive hydrocellular
dressing.‡ In either case, treatment was given for 4
weeks and patients were followed up for up to an
additional 8 weeks or to complete wound closure,1807
Assessment of Patient Eligibility
Consent and Patient Enrollment
Baseline Clinical Assessment (Within 5
Days to Before Initiation of Treatment)
Randomization
(n=48)
Clostridial Collagenase Ointment
(n=24)
Treatment Continued
for 4 Weeks
Discontinuation - 5 Patients
Reasons: Adverse Event Unrelated
to Treatment = 3 Patients; Patient
or Investigator Decision or Lost-to-
follow-up = 2 Patients
Discontinuation - 3 Patients
Reasons: Adverse Event Unrelated
to Treatment = 2 Patients; Patient
or Investigator Decision or Lost-to-
follow-up = 1 Patient
Treatment
Duration
Allocation
Follow-up for
Additional 8
Weeks
Analysis at 12
Weeks
ITT Population (n=24) ITT Population (n=24)
Treatment Continued
for 4 Weeks
Saline Moistened Gauze/Selective
Sharp Debridement (n=24)
Figure 1. Flowchart of patient enrollment and study schema. ITT ¼ intent to treat.
§Trademark: Mepitels (Mölnlycke Health Care, Norcross,
Georgia).
‖Trademark: Copas (Covidien, Mansﬁeld, Massachusetts).
Clinical Therapeuticswhichever came ﬁrst. All patients agreed to wear an
ofﬂoading boot or other appropriate device to aid the
wound healing. Patients randomized to the SMG group
received surgical debridement, as deemed medically
necessary by the investigator, at any weekly visit.
Patients randomized to the CCO group received
surgical debridement if deemed medically necessary.
Patients were seen every week during the treatment
and follow-up phases. Patients were instructed in daily
wound cleansing with sterile saline, dressing changes,
and application of either CCO or SMG. Patients
randomized to the SMG group were told to gently
peel away the dressing moistening with sterile saline to
facilitate removal. At the end of the 4-week treatment
period and throughout follow-up, wounds were1808dressed daily with a soft silicone contact layer§
covered by foam dressing‖.Study Assessments
The primary efﬁcacy analysis was a treatment
group comparison of changes from baseline in wound
status total score using a standardized wound assess-
ment method (Table II), modiﬁed from the Bates-
Jensen Wound Assessment Tool,35 including wound
edge appearance, undermining, necrotic tissue type,
necrotic tissue amount, exudate type, exudate amount,Volume 35 Number 11
Table II. Standardized Wound Assessment Tool.*
Item Assessment
Edges 1 ¼ Indistinct, diffuse, none clearly visible
2 ¼ Distinct, outline clearly visible, attached, even with wound base
3 ¼ Well-deﬁned, not attached to wound base
4 ¼ Well-deﬁned, not attached to base, rolled under, thickened
5 ¼ Well-deﬁned, ﬁbrotic, scarred or hyperkeratotic
Undermining 1 ¼ None present
2 ¼ Undermining o2 cm in any area
3 ¼ Undermining 2–4 cm involving o50% wound margins
4 ¼ Undermining 2–4 cm involving 450% wound margins
5 ¼ Undermining 44 cm or tunneling in any area
Necrotic tissue type 1 ¼ None visible
2 ¼ White/gray nonviable tissue and/or nonadherent yellow slough
3 ¼ Loosely adherent yellow slough
4 ¼ Adherent, soft, black eschar
5 ¼ Firmly adherent, hard, black eschar
Necrotic tissue amount 1 ¼ None visible
2 ¼ o25% of wound bed covered
3 ¼ 25%–50% of wound covered
4 ¼ 450% and o75% of wound covered
5 ¼ 75% to 100% of wound covered
Exudate type 1 ¼ None
2 ¼ Bloody
3 ¼ Serosanguineous: thin, watery, pale red/pink
4 ¼ Serous: thin, watery, clear
5 ¼ Purulent: thin or thick, opaque, tan/yellow, with or without odor
Exudate amount 1 ¼ None, dry wound
2 ¼ Scant, wound moist but no observable exudate
3 ¼ Small
4 ¼ Moderate
5 ¼ Large
Skin color surrounding wound 1 ¼ Pink or normal for ethnic group
2 ¼ Bright red and/or blanches to the touch
3 ¼ White or gray pallor or hypopigmented
4 ¼ Dark red or purple and/or nonblanchable
5 ¼ Black or hyperpigmented
Granulation tissue 1 ¼ Skin intact or partial thickness wound
2 ¼ Bright, beefy red; 75%–100% of wound ﬁlled and/or tissue overgrowth
3 ¼ Bright, beefy red; between 25% and 75% of wound ﬁlled
4 ¼ Pink or dull dusky red and/or ﬁlls r25% of wound
5 ¼ No granulation tissue present
*Modiﬁed from the Bates-Jensen Wound Assessment Tool.
A. Tallis et al.
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Clinical Therapeuticsperiwound skin color, and granulation tissue appea-
rance, at each of the 4 treatment period visits for the
intent-to-treat (ITT) population. Secondary efﬁcacy
was assessed as percentage of the wound area change
from baseline during the 4-week treatment period and
at the end of the follow-up period. The wound area
was measured manually with a ruler as length of long
axis  greatest width perpendicular to long axis.
Lastly, a post hoc analysis was performed on the
response rates of the 2 debridement modalities at
the 12-week end-of-study (EOS) visit. The response
rate were categorized as follows: a reduction in the
baseline wound surface area (WSA) of r10% at the
12-week EOS visit was classiﬁed as a stalled wound, a
reduction in baseline WSA 410% but o50% was
classiﬁed as a moderate response, and a reduction in
baseline WSA Z50% at the 12-week EOS visit was
classiﬁed as a large response.
Neuropathy was conﬁrmed by subject inability to
perceive 10 g of pressure in the periwound area using
a nylon monoﬁlament test. Adequate perfusion to the
affected foot was conﬁrmed by either a transcutaneous
oxygen pressure 440 mm Hg, a great toe pressure of
440 mm Hg, or Doppler waveform consistent with
adequate blood ﬂow.
Tolerability was assessed through analysis of ad-
verse events. Adverse events were collected from the
date a patient provided informed consent through
follow-up and exit from the study.
Resource Use and Costs
A cost-effectiveness analysis was performed (Excel
2007; Microsoft, Redmond, Washington) to evaluate
the cost per responder between the 2 therapeutic
alternatives. The portion of patients with a positive
response served as the clinical measure of effectiveness
in the economic analysis. Similar to the clinical trial,
the time horizon for the economic analysis was 12
weeks. The economic analysis assumes that the costs
for DFU cover dressings were essentially the same
between the 2 debridement approaches and conse-
quently were not included in the assessment of
resource use and cost.
Because this is neither a Markov nor decision
analytic model, there is no model structure per se.
This is simply an economic report of the incremental
resources used in the prospective clinical trial and
their associated incremental costs relative to the
clinical outcomes. Resource use estimates for DFU1810therapy include frequency of selective sharp debride-
ment procedures and physician ofﬁce visits associated
with the evaluation and management of DFU patients
and collagenase ointment use.
Collagenase ointment use was estimated based on
WSA and proper allocation guidelines using the
following equation:
CU ¼ cm2  PA pco  28 days
where CU is collagenase use, cm2 is the WSA (2.7
cm2), PA is proper application (0.2 cm thick, applied
daily), and Pco is the density of collagenase ointment
(0.8 g/mL).
On the basis of the collagenase ointment use
formula, it was estimated that one 30-g tube of
collagenase ointment per patient was necessary to
complete the full 4-week treatment period. Costs
between the 2 debridement alternatives were estimated
for both the physician ofﬁce and the wound clinic
facility (hospital outpatient department wound care
center) settings of care. The CMS varies reimburse-
ment rates based on settings of care (eg, wound clinic
facility vs physician ofﬁce). Moreover, the CMS
reimburses wound clinic facilities for overhead costs
associated with the provision of patient care per-
formed at the wound clinic facility. Resource costs
were taken from standard cost references as listed in
Table III. Only direct costs of debridement and patient
evaluation and management were used in the analysis.
The economic perspective included in the study was
based on the reimbursement by the payer (ie, CMS).
No cost discounting was performed because of the
short time horizon of the analysis (12 weeks).
The direct costs of debridement and patient evalu-
ation and management were calculated using the
following equation:
n
CCX¼∑Rt  C
t¼1
where CCx is the cumulative cost for therapy x, Rt is
the resources in units used at time t, C is the cost of
resource per unit, and t is time in weeks.
Statistical Analysis
The change from baseline in the wound assessment
scores for the 2 treatment groups were compared at
each of the 4 postbaseline treatment weeks and at the
end of the follow-up period using a mixed-effectsVolume 35 Number 11
Table III. Resources and Associated Costs in the Prospective, Randomized, 12-Week Clinical Study.
Resource
Code (CPT, HCPCS,
NDC, APC)
Cost
(US $) Source
Evaluation and management physician ofﬁce visit
(wound clinic facility)
99212 25.19 CMS
Evaluation and management physician ofﬁce
visit (physician ofﬁce)
99212 42.55 CMS
Selective sharp debridement (wound clinic facility) 97597 23.83 CMS
selective sharp debridement (physician ofﬁce) 97597 75.22 CMS
Evaluation and management facility use 0605 72.12 CMS
Selective sharp debridement use G0247 104.86 CMS
Collagenase ointment 30-g tube 00064-5010-30 176.92 Smith & Nephew
APC ¼ Ambulatory Payment Classiﬁcation; CMS ¼ Centers for Medicare and Medicaid Services; CPT ¼ Current Procedural
Terminology; HCPCS ¼ Healthcare Common Procedural Coding System; NDC ¼ National Drug Code.
A. Tallis et al.analysis of covariance for the ITT population. Treat-
ment and treatment week, as well as their interaction,
were deﬁned as ﬁxed effects, with patients as a
random effect. The corresponding wound assessment
score at baseline was used as a covariate. Missing
values for any of the individual subscales were
imputed with the mean score for that assessment (at
that visit) and rounded up to the nearest integer
provided that the total number of missing subscale
values did not exceed 20% of the total item number.
Otherwise, the assessment score was set to missing.
Missing wound area measures at any of the treatment
weeks, resulting from wound healing, early discontin-
uations, or any other reason, were imputed using the
method of last observation carried forward. Paired t
tests were used to assess the change from baseline in
wound area. A χ2 likelihood ratio test was used to
assess the differences in response rates between the 2
debridement alternatives. All efﬁcacy data were ana-
lyzed in the ITT population, deﬁned as all randomized
patients. A signiﬁcance level of P o 0.05 was used in
all statistical analyses.Sample Size
The number of patients (N ¼ 40) was calculated to
be sufﬁcient to detect an effect size (Cohen’s d) of 0.80
with α ¼ 0.05 and 1  β ¼ 0.80. Given the short time
and standard nature of treatments used in the study,November 2013dropouts were expected to be o10%. Assuming a
10% attrition rate, the sample size was set at 24
patients in each arm. Therefore, it was expected that
at least 20 patients from each group would complete
the study.RESULTS
The study was conducted from April 2010 to August
2011 at 7 sites in the United States. A total of 48
patients with DFUs were randomized at 7 sites (24 to
each group). Demographic and baseline wound charac-
teristics are given in Table IV. The mean (SD) age
of the patients was 61.0 (11.8) years. Most patients
were white (94%) and male (67%). No signiﬁcant
differences were found between the CCO and SMG
groups for any demographic variables. The DFUs were
located primarily on the plantar surface (60%) and were
round or oval in shape (60%), with a mean ulcer area
of 2.7 cm2 (range, 0.5-9.25 cm2). No signiﬁcant diffe-
rences were found in the characteristics of DFUs
between the 2 groups.
Eight patients discontinued participation before
study completion (n ¼ 5 in the CCO group and n ¼
3 in the SMG group). The most frequent reason was
an adverse event unrelated to test article (n ¼ 3 in the
CCO group and n ¼ 2 in the SMG group), with the
remainder due to either patient or investigator deci-
sion or lost to follow-up (Figure 1).1811
Table IV. Demographic and Baseline Wound Characteristics.
Treatment Group
Characteristic Total (N ¼ 48) CCO (n ¼ 24) SMG (n ¼ 24) P (ANOVA or χ2 Test)
Age (y)
Mean 61.0 58.5 63.5 0.1483
Median 61.0 59.0 63.5
SD 11.8 13.3 9.8
Range 38–86 38–86 47–85
Age group, No. (%)
o65 years 28 (58) 15 (62) 13 (54)
Z65 years 20 (42) 9 (38) 11 (46)
Sex, No. (%)
Female 16 (33) 8 (33) 8 (33) 40.99
Male 32 (67) 16 (67) 16 (67)
Race/ethnicity, No. (%)
Black/African American 3 (6) 2 (8) 1 (4) 0.5510
White 45 (94) 22 (92) 23 (96)
Hispanic/Latino 9 (19) 5 (21) 4 (17) 0.7115
Non-Hispanic/non-Latino 39 (81) 19 (79) 20 (83)
Wound area (cm2)
Mean 2.7 3.0 2.4 0.3014
Median 1.9 2.6 1.6
SD 2.1 2.1 2.1
Range 0.5–9.0 0.5–9.0 0.5–7.6
Wound location, No. (%)
Distal 3 (6) 2 (8) 1 (4) 0.6003
Dorsal 4 (8) 1 (4) 3 (12)
Lateral 4 (8) 2 (8) 2 (8)
Medial 2 (4) 2 (8) —
Plantar 29 (60) 15 (62) 14 (58)
Plantar/distal 5 (10) 2 (8) 3 (12)
Plantar/lateral 1 (2) — 1 (4)
Wound side, No. (%)
Left 21 (44) 10 (42) 11 (46) 0.7711
Right 27 (56) 14 (58) 13 (54)
Wound shape, No. (%)
Bowl/boat 2 (4) 2 (8) — 0.3059
Irregular 17 (35) 9 (38) 8 (33)
Round/oval 29 (60) 13 (54) 16 (67)
CCO ¼ clostridial collagenase ointment; SMG ¼ saline moistened gauze.
Clinical TherapeuticsWound Assessment Scores
The wound assessments consisted of 8 subscales
from the Bates-Jensen Wound Assessment Tool. Each1812subscale had a possible score of 1 to 5, with 1
indicating intact skin and 5 indicating the worst
possible rating. The combined score could thus rangeVolume 35 Number 11
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A. Tallis et al.from 8 for normal skin to 40 for an ulcer that has
hyperkeratotic edges, no granulation tissue, complete
coverage with hard black eschar, and large amounts
of purulent exudate. Mean wound assessment scores
were not signiﬁcantly different among the CCO and
SMG groups at baseline, at any of the treatment visits
(weeks 1–4), or at study exit (Figure 2). Signiﬁcant
improvement in mean total scores was seen for both
groups beginning as early as 1 week after the start of
treatment for the CCO group (P ¼ 0.005) and at 2
weeks after the start of treatment for the SMG group (P
¼ 0.049). No signiﬁcant differences were seen between
the 2 treatment groups for any of the individual wound
assessment subscales at any assessment time point (data
not shown). Mean (SD) wound assessment total score at
week 12 was 14.5 (5.6) (95% CI, 12.3–16.7) for the
CCO group and 13.8 (6.4) (95% CI, 11.2–16.4) for the
SMG group. The decrease in mean (SD) total score at
week 12 from baseline was 3.7 (5.2) for the CCO group
and 3.5 (7.1) for the SMG group. The scores at week 12
correspond to a mean subscale score of 1.8 and 1.7,
respectively. Both treatment groups provided a clinicallyNovember 2013meaningful reduction from baseline in wound assess-
ment total score.
Examination of the exudate amount subscale pro-
vides useful information regarding the wound environ-
ment in terms of moisture. CCO is formulated in an
occlusive petrolatum base, whereas gauze, if not
moistened and when applied to ulcers with little or
no exudate, could result in a dry ulcer environment.
The exudate amount subscale score deﬁnitions are
given in Table II. No signiﬁcant differences were found
between the CCO and SMG groups in this assessment
at any of the treatment weeks or at study exit (mean
values for treatment weeks 1–4 and study exit: CCO,
2.3, 2.0, 2.1, 2.2, and 1.9; SMG: 2.0, 2.1, 1.7, 1.8, and
1.9). Values for both groups at all assessment time
points were approximately 2, corresponding to a moist
wound with scant exudate.
Percentage Change in DFU Area
DFUs randomized to CCO had a mean percent
change from baseline in area of 44.9% at the end of
treatment visit and 53.8% at study exit. Both ﬁndings1813
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Figure 4. Response rates at week 12 study exit.
Large response (ulcer area reduction
from baseline Z50%), moderate re-
sponse (ulcer area reduction from
baseline o50% but 410%), stalled
response (ulcer area reduction from
baseline r10%, or increase in size).
CCO ¼ clostridial collagenase oint-
ment; SMG ¼ saline moistened gauze.
Clinical Therapeuticswere statistically signiﬁcant (P ¼ 0.016; P ¼ 0.012). The
corresponding changes for the SMG group were þ0.8%
at end of treatment and þ8.1% at study exit; neither
was signiﬁcantly different from baseline (Figure 3). The
relatively poor outcome observed for the SMG group
should not be interpreted to mean that none of the DFUs
in the SMG group failed to improve in healing. In a post
hoc analysis assessed at the 12-week study exit visit,
patients were categorized as having a large response
(ulcer area reduction from baselineZ50%), a moderate
response (ulcer area reduction from baselineo50% but
410%, a stalled response (ulcer area reduction from
baseline r10%, or an increase in size) (Figure 4).
Although there were similar numbers of large
responses in the 2 groups at the end of study visit
(week 12), there were more stalled ulcers in the SMG
group (n ¼ 5) compared with the CCO group (n ¼ 1)
and more moderate responses in the CCO group (n ¼ 6)
compared with the SMG group (n ¼ 1). This imbalance
in clinical response between the 2 alternative
debridement modalities was statistically signiﬁcant (P
o 0.05).
The mean number of surgical debridements per-
formed on DFUs during the entire study (treatment
and follow-up periods combined) was 6.9 for the1814SMG group and 1.0 (the baseline debridement) for the
CCO group. During the posttreatment follow-up
period, a mean of 2.8 debridements were performed
in the SMG group compared with 0 in the CCO
group. There was a single instance of sharp debride-
ment after the treatment phase in the CCO group;
however, this did not affect the mean. Both groups
had approximately 4 follow-up visits after treatment.
Tolerability
Of the 48 patients, 23 experienced 61 treatment-
emergent adverse events. Adverse events were distrib-
uted evenly between the treatment groups, with 28
reported in the CCO group and 33 in the SMG group.
Most were considered mild (51%) or moderate
(39%). Reported adverse events were similar between
the 2 treatment groups. None of the reported adverse
events were assessed as being related to treatment by
the investigators.
Health Economic Outcomes
The mean number of physician evaluation and
management visits per patient was 12 in the CCO
group and 6 in the SMG group. The mean numbers of
surgical debridements performed in the clinical trialVolume 35 Number 11
Table V. Comparative Cost-Effectiveness of SMG and CCO in the Prospective, Randomized, 12-Week
Clinical Study.
Payer (CMS) Costs (US $)
Physician Ofﬁce Wound Clinic Facility
SMG CCO SMG CCO
Selective Sharp Debridement
No. of debridements
Mean 7 1 7 1
Median (range) 5 (2–12) 1 (1–2) 5 (2–12) 1 (1–2)
CMS cost per debridement* (US $) 75 75 129 129
Total debridement costs (US $)
Mean 527 75 901 129
Median (range) 376 (150–903) 75 (75–150) 643 (257–1544) 129 (129–257)
Evaluation and Management
No. of visits
Mean 6 12 6 12
Median (range) 5 (2–12) 12 (11–12) 5 (2–12) 12 (11–12)
Cost per visit* (US $) $43 $43 $97 $97
Total costs of visits (US $)
Mean 255 511 584 1168
Median (range) 340 (43–468) 511 (618–945) 778 (97–1070) 1168 (1070–1168)
CCO
No. of CCO tubes
Mean 0 1 0 1
Median (range) — 1 (1–2) — 1 (1–2)
Cost per CCO tube* (US $) 0 177 0 177
Total CCO cost (US $)
Mean 0 177 0 177
Median (range) — 177 (177–354) — 177 (177–354)
Total cost of the therapy (US $)
Mean 782 763 1485 1473
Median (range) 717 (618–945) 763 (763–940) 1422 (1328–1642) 1473 (1473–1650)
Mean (SD) response rates 0.75 (0.41) 0.92 (0.28) 0.75 (0.41) 0.92 (0.28)
Cost per responder (US $)
Mean 1042 832 1980 1607
Median (range) 955 (1260–825) 829 (1021–829) 1546 (1784–1443) 1601 (1794–1601)
CMS ¼ Centers for Medicare and Medicaid services; CCO ¼ clostridial collagenase ointment; SMG ¼ saline
moistened gauze.
*National mean CMS allowable costs.
A. Tallis et al.were 1 and 7 per patient in the CCO and SMG
groups, respectively. As stated in the Patients and
Methods section, the amount of collagenase ointment
used per patient was 1 30-g tube per patient in the
CCO group (Table V).November 2013The ﬁndings presented in Table V give the
estimated cost differences by physician ofﬁce versus
wound clinic facility between the SMG and CCO
groups at the end of the 12-week study. The physician
ofﬁce mean cost of debridement per patient in the1815
Clinical TherapeuticsSMG group was 46-fold higher than in the CCO
group (US $527 vs $75) for the management of DFUs.
Conversely, the physician ofﬁce mean cost of evalua-
tion and management visits per patient in the CCO
group was 2-fold higher than in the SMG group (US
$511 vs $255). In addition, the CCO group incurred
US $177 per patient for collagenase ointment. Overall,
the cost-effectiveness ratios were US $1042 versus $832
per responder in the SMG and CCO groups, respec-
tively, for DFU therapy in the physician ofﬁce setting.
A similar trend in economic outcomes was derived
in the wound clinic facility setting for the 2 treatment
approaches in the management of DFU. The wound
clinic facility’s mean cost of debridement per patient in
the SMG group was 7-fold higher compared with
the CCO group (US $901 vs US $129). However, the
wound clinic facility’s mean cost of evaluation and
management visits per patient in the CCO group was
twice that of SMG group (US $1168 vs $584). The
collagenase ointment costs remain unchanged from
physician ofﬁce setting to wound clinic facility setting.
Overall, the cost-effectiveness ratios were US $1980
versus $1607 per responder in the SMG and CCO
groups, respectively, for DFUs treated in the hospital
outpatient department wound care clinic (Table V).
DISCUSSION
The management of DFU remains a major therapeutic
challenge to the treating physicians, surgeons, and
other health care professionals. There is an urgent
need for new strategies with clinically effective med-
icines to treat DFUs to reduce the burden of care in an
efﬁcient and cost-effective way. To promote healing of
DFUs, a healthy ulcer environment must be created by
removing necrotic tissue, managing bacterial load, and
maintaining an appropriate moisture balance.
Standard treatment for DFU has been wound bed
preparation by removal of necrotic tissue, reducing
excessive ulcer exudate, decreasing bacterial level, and
elimination of deleterious chemical mediators. Ulcer
debridement is necessary for removal of devitalized
tissue to create an optimal wound bed. Removal of
nonviable tissue permits better visualization of the
wound base, removes a growth medium for bacteria,
and stimulates release of growth factors. In addition,
repeated or maintenance debridement of DFUs is
required whenever devitalized tissue is present.14,36
A variety of techniques have been commonly used for
wound debridement in clinical practice. The choice of1816debridement methods depends on the clinician. Enzy-
matic debridement using CCO is an efﬁcient alter-
native treatment approach to surgical debridement.
Several studies have reported that enzymatic debride-
ment using CCO is tolerable and clinically effective in
achieving the removal of nonviable tissue in wound
bed preparation.20,22,23,26,37,38
In this study, we assessed the clinical efﬁcacy,
tolerability, and costs of enzymatic debridement
(CCO) in diabetic patients with foot ulcers. The study
primarily focused on examining the wound healing
properties, such as reduction in WSA and ulcer bed
condition, after CCO or SMG therapy. In addition, we
assessed and compared the health economic outcomes
after CCO or SMG therapy. To our knowledge, this is
the ﬁrst randomized, prospective study that evaluated
and compared the clinical efﬁcacy, tolerability, and
costs of enzymatic debridement using CCO to stand-
ard debridement in patients with DFUs. The ﬁndings
clearly indicate that daily treatment with collagenase
ointment is as effective as daily treatment with SMG
and weekly sharp debridement. When compared with
baseline, wound assessment scores improved signiﬁ-
cantly at each treatment visit with CCO, indicating
that CCO provides effective debridement. A similar
improvement in wound assessment scores was also
observed in the SMG group from baseline. However,
the differences in the wound assessment scores were
not signiﬁcantly different between the CCO and SMG
groups, indicating similar debridement efﬁcacy. The
results of the study are consistent with those previously
published reports in which collagenase was found to
provide complete and effective debridement of pres-
sure ulcers without sharp surgical debridement.37
Earlier studies have found that CCO therapy accel-
erates wound healing through mechanisms distinct,
although consequent to its debridement activ-
ity.20,27,29,30 The results of the present study are con-
sistent with such a mechanism. DFUs treated with either
CCO or SMG had by the end of the 4-week treatment
period signiﬁcant and clinically relevant improvement in
the wound bed (as documented by decreases in the
wound assessment scores). However, at the end of
treatment, mean reduction from baseline in wound area
for the DFUs treated with CCO was statistically signiﬁ-
cant (reductions in wound area of 50%) but not for
the SMG treatment group. Moreover, mean reduction in
wound area continued (albeit more slowly) throughout
the 8-week (untreated) follow-up period for the CCOVolume 35 Number 11
A. Tallis et al.group, whereas the mean wound area remained static
for the SMG group. It is worth noting that this differ-
ence in the mean healing between the 2 groups is
primarily due to the inﬂuence of several stalled ulcers.
One-fourth of the ulcers in the SMG group did not
progress toward closure (or actually enlarged), whereas
only 1 to 2 ulcers of the 24 treated with CCO (depend-
ing on the time point) were categorized as stalled.
It is well established that clostridial collagenase is
speciﬁc for peptide bonds in the triple helical domains of
collagen. At therapeutic doses, it can only digest collagen
but not keratin, fat, or ﬁbrin; thus, it has no effect
on intact skin.20 Because it speciﬁcally attacks collagen
and attacks speciﬁc peptide bonds, only a subset of all
possible proteolytic fragments is produced. These peptide
fragments may inﬂuence cellular activities, such as
migration and proliferation.27 The healing beneﬁts of
CCO may thus be unique and not generalizable to other
proteases. In addition, collagenase itself may contribute
to the migration and activity of important cells, such as
wound macrophages, ﬁbroblasts, and keratinocytes, and
promote ulcer healing.39
In this study, the number of surgical debridements
performed was not a planned end point; however, the
difference in debridement frequency between the 2
groups merits discussion. On the basis of clinical need,
surgical debridement was performed in the SMG
group at weekly visits. If surgical debridement was
deemed necessary for a patient in the CCO group, the
patient was removed from the study because contin-
uation would make a clear-cut distinction between the
groups in regard to removal of healthy tissue and
impact on rate of healing impossible. Nevertheless, the
appearance of the wound was the only factor in the
decision of whether to debride. Investigative sites were
not provided additional compensation for follow-up
study visits if debridement was performed. Only 1
patient in the CCO group required debridement
(during follow-up), whereas each patient in the SMG
group was debrided a mean of 6 times in addition to
baseline debridement performed on all patients. De-
spite no sharp debridement, the CCO group had a
54% reduction in the wound area compared with no
decrease, on average, for the SMG group.
These results further suggest that the wound healing
is accelerated in the CCO group because of continued
effects of collagenase during the rest of the follow-up
period. Unlike endogenous (mammalian) collagenase
that cleaves collagen at 1 site, producing 2 fragments,40November 2013clostridial collagenase cleaves all 3 helical domains of
collagen to produce several breakdown products.41
Thus, the facilitation of early debridement in the
CCO group could be because collagenase acts as the
rate-determining enzyme in collagen degradation, cata-
lyzing cleavage of native collagen triple helix. With its
speciﬁcity, collagenase could promote debridement by
digesting collagen bundles that bind nonviable tissue to
the wound bed. In addition, collagenase may provide
additional beneﬁts to DFUs that go beyond debride-
ment while decreasing the need for frequent surgical
debridement. Additional beneﬁts of collagenase could
be that it promotes the migration and proliferation of
vascular endothelial cells and keratinocytes39 and the
release and activation of endogenous promoters of
growth. Moreover, there is ample evidence to indicate
that collagenase not only successfully debrides wounds
but also hastens wound closure.29
Health economic beneﬁts assessed through the cost-
effectiveness analysis have been used as indicators to
improve the allocation of scarce health care resour-
ces.10,42–44 Given ﬁnite resources, efﬁcient allocation
of resources is required to optimize the health beneﬁt
per dollar spent on providing care for the patients.
DFUs signiﬁcantly affect patient resource use and
costs. Therefore, we assessed the cost-effectiveness
associated with the CCO treatment and compared it
with the SMG therapy for the management of DFUs.
Our ﬁndings clearly indicate that CCO treatment is
more cost-effective than SMG in promoting the heal-
ing of DFUs. In this study, CCO debridement of DFUs
produced better results than selective sharp debride-
ment at similar costs of care.
The strength of the study was that it was a
prospective, parallel group, open-label, multicenter,
randomized trial that compared head to head the
clinical and health outcomes of CCO and SMG in
conjunction with surgical debridement in the manage-
ment DFUs. However, the 12-week trial duration was
comparatively short, considering that DFU healing
studies often last Z20 weeks. A limitation of this
study was that the decision regarding the necessity of
debridement was left to the subjective judgment of
individual investigators. In addition, it was a small
study with 12-week follow-up, and the health eco-
nomics ﬁndings are sensitive to the number of debride-
ment procedures performed relative to the number of
physician evaluation and management visits of the
patients. In addition, the WSA, which has a direct1817
Clinical Therapeuticsrelationship on the amount of collagenase ointment,
may inﬂuence the health economics ﬁndings of the
study. Moreover, because this study was based on
Medicare and Medicaid reimbursement assumptions,
the health economics outcomes may not be represen-
tative of all patients with different types of insurance.
An additional shortcoming of the study was that the
health economic outcomes cannot be generalized to
wounds of other origins and to care provided in non–
ambulatory care settings. Nonetheless, this study has
shed light on the clinical and health economics of 2
treatment approaches in providing care for patients
with DFUs.
CONCLUSIONS
The results of the study indicate that CCO is tolerable
and clinically effective in achieving the removal of
nonviable tissue in the preparation of a healthy wound
bed. The clinical utility of CCO is better or compara-
ble to that of standard of care with SMG plus weekly
sharp debridement. Signiﬁcant improvement in wound
bed appearance was obtained more rapidly with CCO
therapy than SMG therapy. In addition, CCO-treated
DFUs had an enhanced rate of healing during the
treatment period and for several weeks after the
cessation of treatment, whereas the SMG therapy
had no effect. Moreover, the clinical beneﬁts with
CCO accrued in the absence of additional surgical
debridement, whereas patients in the SMG group
continue to require surgical debridement during
follow-up.
Although delivering similar or better clinical out-
comes, depending on the clinical assessment used,
enzymatic debridement of DFUs with CCO offers
better value compared with the SMG regardless of
the ambulatory care setting. In particular, CCO
therapy is a cost-effective method of debridement
in the management of patients with DFUs.
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